LCI - Lannett Company, Inc.
| Previous Close | 24.50 |
| Open | 23.90 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 23.60 - 24.65 |
| 52 Week Range | 14.90 - 27.90 |
| Volume | 549,140 |
| Avg. Volume | 782,010 |
| Market Cap | 902.28M |
| Beta | 1.95 |
| PE Ratio (TTM) | -1,210.00 |
| EPS (TTM) | -0.02 |
| Earnings Date | Nov 1, 2017 - Nov 6, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.00 |
- Capital Cube•2 days ago
ETFs with exposure to Lannett Co., Inc. : October 20, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Lannett Co., Inc. Here are 5 ETFs with the largest exposure to LCI-US. Comparing the performance and risk of Lannett Co., Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- Capital Cube•13 days ago
ETFs with exposure to Lannett Co., Inc. : October 9, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Lannett Co., Inc. Here are 5 ETFs with the largest exposure to LCI-US. Comparing the performance and risk of Lannett Co., Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Capital Cube•16 days agoLannett Co., Inc. :LCI-US: Earnings Analysis: Q4, 2017 By the Numbers : October 6, 2017
Categories: Yahoo FinanceGet free summary analysis Lannett Co., Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 139.12 million, Net Earnings of USD 5.73 million. Gross margins narrowed from 47.33% to 42.32% compared to the same period last year, operating (EBITDA) margins now 32.19% from 34.56%. Change in operating ... Read more (Read more...)
- Simply Wall St.•20 days ago
Lannett Company Inc (LCI): What Does It Mean For Your Portfolio?
For Lannett Company Inc’s (NYSE:LCI) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Every stock inRead More...
- PR Newswire•20 days ago
Lannett Receives Two FDA Approvals For Lansoprazole Delayed-Release Capsules USP, One Each For Full Prescription And OTC
--Company Cleared to Market Prescription and OTC Generic Prevacid®-- PHILADELPHIA , Oct. 2, 2017 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. ...
- ACCESSWIRE•23 days ago
Corporate News Blog - Lannett Gets FDA Approval for Oxycodone and Acetaminophen Tablets USP
LONDON, UK / ACCESSWIRE / September 29, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Lannett Co., Inc. (NYSE: LCI ), following which we have published ...
- Capital Cube•24 days ago
ETFs with exposure to Lannett Co., Inc. : September 28, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Lannett Co., Inc. Here are 5 ETFs with the largest exposure to LCI-US. Comparing the performance and risk of Lannett Co., Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Capital Cube•24 days agoLannett Co., Inc. breached its 50 day moving average in a Bullish Manner : LCI-US : September 28, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Lannett Co., Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)
- PR Newswire•25 days ago
Lannett Receives FDA Approval For Oxycodone And Acetaminophen Tablets USP, 5 mg/325 mg And 10 mg/325 mg
PHILADELPHIA , Sept. 27, 2017 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application ...
- PR Newswire•26 days ago
Lannett Receives Approval For Dexmethylphenidate Hydrochloride Tablets, 2.5 mg, 5 mg And 10 mg
PHILADELPHIA , Sept. 26, 2017 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application ...
- PR Newswire•26 days ago
Lannett Announces Dismissal Of Class Action Lawsuit
PHILADELPHIA , Sept. 26, 2017 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that the United States District Judge for the Eastern District of Pennsylvania dismissed in its entirety ...
- PR Newswire•27 days ago
Lannett's Board Of Directors Initiates CEO Search
--CEO Arthur Bedrosian to Step Down Upon Naming of a Successor-- --Company Submits 505(b)(2) New Drug Application for Its Proprietary Anesthetic Product, Cocaine Hydrochloride (HCl) Topical Solution-- ...
- PR Newswire•last month
Arthur Bedrosian, Lannett CEO, Prevails In Lawsuit With Internal Revenue Service
PHILADELPHIA , Sept. 22, 2017 /PRNewswire/ -- Arthur Bedrosian, chief executive officer of Lannett Company, Inc. (NYSE: LCI), has prevailed in his lawsuit with the U.S. Internal Revenue Service (IRS). ...
- ACCESSWIRE•last month
Earnings Review and Free Research Report: Lannett’s Sales and Earnings Results Met Expectations
Research Desk Line-up: Catalent Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 13, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Lannett Co., Inc. (NYSE: LCI ), ...
- Simply Wall St.•2 months ago
What Is Lannett Company Inc’s (LCI) Share Price Doing?
Lannett Company Inc (NYSE:LCI), a pharmaceuticals, biotechnology and life sciences company based in United States, saw a double-digit share price rise of over 10% in the past couple of monthsRead More...
- TheStreet.com•2 months ago
Lannett Scores FDA OK for Nexium Generic-Biotech Movers
Cellect Biomd was up after securing orphan drug status for its transplant anti-rejection drug.
- PR Newswire•2 months ago
Lannett Receives Approval For Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg And 40 mg
PHILADELPHIA , Sept. 5, 2017 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application ...
- Capital Cube•2 months ago
ETFs with exposure to Lannett Co., Inc. : September 2, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Lannett Co., Inc. Here are 5 ETFs with the largest exposure to LCI-US. Comparing the performance and risk of Lannett Co., Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Capital Cube•2 months agoLannett Co., Inc. :LCI-US: Earnings Analysis: 2017 By the Numbers : August 30, 2017
Categories: Yahoo FinanceGet free summary analysis Lannett Co., Inc. reports financial results for the year ended June 30, 2017. We analyze the earnings along side the following peers of Lannett Co., Inc. – Impax Laboratories, Inc., Pfizer Inc., Johnson & Johnson, Mylan N.V., GlaxoSmithKline plc Sponsored ADR, Akorn, Inc., Abbott Laboratories and Novartis AG Sponsored ADR (IPXL-US, ... Read more (Read more...)
- Zacks•2 months ago
Lannett (LCI) Q4 Earnings In Line, Stock Up on Solid View
Lannett (LCI) reported in-line Q4 earnings and sales. The FDA approved multiple pending ANDAs during the quarter. Also, the company provided strong outlook for 2018.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of LCI earnings conference call or presentation 23-Aug-17 8:30pm GMT
Q4 2017 Lannett Company Inc Earnings Call
- Associated Press•2 months ago
Lannett posts 4Q profit
On a per-share basis, the Philadelphia-based company said it had net income of 15 cents. Earnings, adjusted for non-recurring costs, came to 40 cents per share. The generic drug company posted revenue ...
- PR Newswire•2 months ago
Lannett Reports Fiscal 2017 Fourth-Quarter And Full-Year Financial Results, Provides Guidance For Fiscal 2018
PHILADELPHIA , Aug. 23, 2017 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2017 fourth quarter and full year ended June 30 , 2017. "In the coming ...
- ACCESSWIRE•2 months ago
Investor Network: Lannett Company, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 23, 2017 / Lannett Company, Inc. (NYSE: LCI ) will be discussing their earnings results in their Q4 Earnings Call to be held August 23, 2017 at 4:30 PM Eastern Time. ...
